Roche’s Board of Directors has appointed Thomas Schinecker as the new Group CEO, effective March 14, 2023. Roche plans to propose Severin Schwan as new chairman at the 2023 Annual General Meeting.
The Board also appointed Mark Schneider, CEO of Nestlé SA, and Professor Akiko Iwasaki, Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University and Howard Hughes Medical Institute investigator. I propose to elect you as a new director at the next meeting. Annual meeting, statement added.
It also said board secretary Annette Luthor will be appointed as head of international government relations in April 2023. At the same time, Per-Olof Attinger, currently Head of the CEO Office and Secretary of the Corporate Executive Board, will take over the role of Secretary of the Board.
In addition, the statement said that Roche Pharma CEO and Corporate Executive Committee member Bill Anderson has decided to pursue non-Roche opportunities effective December 31, 2022. His successor he will be appointed by March 2023. Schinecker will become Roche Pharma’s interim CEO from January 1, 2023, with his role at Roche Diagnostics handed over to Matt Sause.
Silke Hernstein, currently Global Head of Strategy and Transformation at Roche Diagnostics, will become Head, Corporate Strategy, Secretary and Corporate Executive Committee in April 2023 and will be a member of the expanded Corporate Executive Committee. Then the statement concludes.
